(Q50890980)

24 March 2018

title

Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. (English)

1 reference

24 March 2018

0 references

1 reference

Kochiadakis GE

1

1 reference

24 March 2018

Igoumenidis NE

2

1 reference

24 March 2018

Marketou ME

3

1 reference

24 March 2018

Solomou MC

4

1 reference

24 March 2018

Kanoupakis EM

5

1 reference

24 March 2018

Vardas PE

6

1 reference

24 March 2018

language of work or name

English

0 references

publication date

1 April 1998

1 reference

24 March 2018

American Journal of Cardiology

published in

1 reference

24 March 2018

volume

81

1 reference

24 March 2018

issue

8

1 reference

24 March 2018

page(s)

995-998

1 reference

24 March 2018

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Therapeutic efficacy and safety of oral propafenone for atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Clinical challenge. I: Control of recurrent symptomatic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Newer developments in the management of atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Comparison of class I and class III action in atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Management of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Amiodarone as a first-line drug in the treatment of atrial fibrillation: the protagonist viewpoint

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Low-dose amiodarone for atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Amiodarone for refractory atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Amiodarone in atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

Risk factors for the development of recurrent atrial fibrillation: role of pacing and clinical variables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900078-2

10.1016/S0002-9149(98)00078-2

7 January 2021

Identifiers

DOI

1 reference

24 March 2018

1 reference

24 March 2018